Real Brands, Inc.

OTC: RLBD · Healthcare · Drug Manufacturers - Specialty & Generic

PublicHQ North Providence, RICIK 0001084133Reports USD

#1059 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ 17GM —SS 33

v0.1 · 25/100 weight · pillars only

↑ net margin, return on assets · ↓ workforce scale, disclosure history

Methodology →

Revenue TTM

$80.7k

Rev growth YoY (TTM)

+204.2%

Net income (FY)

$1.3M

Employees

Market cap

$26.9k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$60.5k$60.5k2023

Net income$1.3M$1.3M2023

Operating income-$1.2M-$1.2M2023

Total assets$1.3M$1.3M2023

Liabilities$2.6M$2.6M2023

Equity-$1.3M-$1.3M2023

Revenue trend

FY2021 – FY2023 · USD

$24.6k

FY21

$5.5k

FY21

$11.1k

FY22

$60.5k

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Real Brands, Inc. booked $60.5k in FY2023 revenue, growing 443% year over year — faster than 94% of Healthcare companies we track, at a 2203.9% net margin.

Peers · Healthcare

Pazoo, Inc.——Net Medical Xpress Solutions, Inc.——EnviroTechnologies International, Inc——Anthera Pharmaceuticals, Inc.——

Key facts

CEOThomas Kidrin

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersNorth Providence, RI

ExchangeOTC: RLBD

Employees1

IPO date2000-11-22

Latest filings

10-Q2024-05-15 8-K2024-05-07 10-K2024-04-01 10-Q2023-11-17 10-Q2023-08-14 10-Q2023-05-15 10-K2023-04-28 8-K2022-12-22

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.